-
Moderna Pipeline For Any Vaccine Beyond Covid Is 'Underappreciated,' Analyst Says
Monday, June 26, 2023 - 10:56am | 244Read More...Shares of Moderna Inc (NASDAQ: MRNA) rose in early trading on Monday, just days after the pharma company submitted an application to the Food and Drug Administration (FDA) for the authorization of an updated vaccine. The stock's current valuation reflects uncertainty around Covid vaccine...
-
Gilead Analysts Trim Expectations After 'Very Unexpected' Adverse FDA Ruling
Wednesday, August 19, 2020 - 11:57am | 685Read More...Gilead Sciences, Inc. (NASDAQ: GILD) faces a regulatory setback as filgotinib, an investigational drug it is co-developing with GALAPAGOS NV/S ADR (NASDAQ: GLPG), received a thumbs-down from the FDA. The Gilead Analyst: BofA Securities analyst Geoff Meacham reiterated a Neutral...
-
5 ASCO Abstracts Moving Biopharma Stocks
Thursday, May 14, 2020 - 3:17pm | 851Read More...The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe. This year's meeting is is scheduled for May 29-31 and is organized as a virtual event due to the...
-
Analysts On Gilead: We Think They're Mobilizing For A Deal
Thursday, May 4, 2017 - 11:53am | 428Read More...Is M&A in the cards for Gilead Sciences, Inc. (NASDAQ: GILD)? Credit Suisse analysts Alethia Young and Eliana Merle think so. In a note reviewing the company's first-quarter results, the analysts said they think the company is mobilizing for a deal. Investors Focus On Potential Deal Credit...
-
Why BioMarin's Pipeline Could Be Worth $4 Billion-Plus
Wednesday, January 20, 2016 - 3:31pm | 251Read More...Credit Suisse issued a report on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and initiated coverage on the company due to strength seen in their drug pipeline. Credit Suisse rates BioMarin as Outperform with a $110 price target. Analysts Alethia Young, Eliana Merle and Grant Hesser highlighted...
